Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

It was a regal achievement for lorlatinib (Lorbrena): The phase III CROWN trial showed that, after 5 years of follow-up, median progression-free survival (PFS) had not yet been reached in patients ...

Thoracic medical oncologists and early drug development specialists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for this patient population.

A comprehensive review of 92 studies found that 15%-20% of lung cancers occurred among nonsmokers and were associated with environmental and germline risk factors. These cancers frequently harbored ...